Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays

[1] Lynch TJ(2004)Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2129-2139

[2] Bell DW(2004)EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 1497-1500

[3] Sordella R(2004)EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci U S A 101 13306-13311

[4] Gurubhagavatula S(2007)Epidermal growth factor receptor mutations in lung cancer Nat Rev Cancer 7 169-181

[5] Okimoto RA(2012)Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer J Clin Oncol 30 3077-3083

[6] Brannigan BW(2009)Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer J Clin Oncol 27 2653-2659

[7] Harris PL(2011)Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors Lung cancer 73 96-102

[8] Haserlat SM(2012)Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer J Thorac Oncol 7 115-121

[9] Supko JG(2006)Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer Clin Cancer Res 12 3915-3921

[10] Haluska FG(2012)EGFR array: uses in the detection of plasma EGFR mutations in non-small cell lung cancer patients J Thorac Oncol 7 1131-1140

[1] Lynch TJ(2004)Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2129-2139

[2] Bell DW(2004)EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 1497-1500

[3] Sordella R(2004)EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci U S A 101 13306-13311

[4] Gurubhagavatula S(2007)Epidermal growth factor receptor mutations in lung cancer Nat Rev Cancer 7 169-181

[5] Okimoto RA(2012)Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer J Clin Oncol 30 3077-3083

[6] Brannigan BW(2009)Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer J Clin Oncol 27 2653-2659

[7] Harris PL(2011)Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors Lung cancer 73 96-102

[8] Haserlat SM(2012)Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer J Thorac Oncol 7 115-121

[9] Supko JG(2006)Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer Clin Cancer Res 12 3915-3921

[10] Haluska FG(2012)EGFR array: uses in the detection of plasma EGFR mutations in non-small cell lung cancer patients J Thorac Oncol 7 1131-1140